Skip to main content

Table 2 Sample characteristics

From: Ranking facilitators and barriers of medication adherence by patients with inflammatory arthritis: a maximum difference scaling exercise

  IA Patients (N = 125)
Age, years (mean, SD) 62.7 (±12)
Sex
 Female 75 (60%)
Diagnosis
 Rheumatoid arthritis 111 (88.8%)
 Ankylosing Spondylitis 4 (3.2%)
 Psoriatic Arthritis 7 (5.6%)
 Other diagnoses 3 (2.4%)
Level of education
 No or pre-primary education 38 (30.6%)
 Primary education and lower secondary education 42 (33.9%)
 Upper secondary education and tertiary education 44 (35.5%)
Disease duration, years (median, IQR) 15 (7, 23)
Pharmacotherapy
 Methotrexate (subcutaneous) 22 (17.6%)
 Methotrexate (oral) 64 (51.2%)
 Leflunomide 3 (2.4%)
 Hydroxychloroquine 29 (23.2%)
 Sulfasalazine 13 (10.4%)
 Gold (oral) 1 (0.8%)
 Infliximab 2 (1.6%)
 Etanercept 15 (12%)
 Adalimumab 7 (5.6%)
 Rituximab 6 (4.8%)
 Abatacept 5 (4%)
 Tocilizumab 11 (8.8%)
  1. IA Inflammatory arthritis; SD Standard deviation